Amicus Therapeutics (2013a). Amicus Therapeutics and GSK announce revised Fabry Agreement. Available at http://ir.amicustherapeutics.com/releasedetail.cfm?ReleaseID=808737 (accessed December2013).
2.
Amicus Therapeutics (2013b). Amicus Therapeutics strengthens Biologics business strategy. Available at http://ir.amicustherapeutics.com/releasedetail.cfm?ReleaseID=808736 (accessed December2013).
3.
Editas Medicine (2013). Editas Medicine created to discover and develop novel class of genome editing therapeutics [Nov. 25, 2013]. Available at http://editasmedicine.com/documents/EditasMedicine-LaunchPR.pdf (accessed December2013).
4.
Food and Drug Administration (2013). Guidance for industry: preclinical assessment of investigational cellular and gene therapy products. Available at www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm376136.htm (accessed December2013).
5.
KoehlerR.N., AltevogtB.M., and GostinL.O., eds. (2013). “Oversight and Review of Clinical Gene Transfer Protocols: Assessing the Role of the Recombinant DNA Advisory Committee,” Institute of Medicine, Committee on the Independent Review and assessment of the Activities of the NIH Recombinant DNA Advisory Comitee, Board on Health Sciences Policy. National Academies Press. www.nap.edu/openbook.php?record_id=18577 (accessed December2013).
6.
Mary Ann Liebert, Inc. publishers (2013). Top 12 pioneer awards for seminal work in gene and cell therapy selected by blue ribbon panel; essays to be published in Human Gene Therapy [Nov. 25, 2013]. Available at www.liebertpub.com/global/pressrelease/top-12-pioneer-awards-for-seminal-work-in-gene-and-cell-therapy-selected-by-blue-ribbon-panel-essays-to-be-published-in-human-gene-therapy/1350/ (accessed December2013).
7.
Oxford BioMedica (2013). Oxford BioMedica receives agreement from FDA and ANSM to resume recruitment into ocular clinical trials. Available at www.oxfordbiomedica.co.uk/press-releases/oxford-biomedica-receives-agreement-from-fda-and-ansm-to-resume-recruitment-into-ocular-clinical-trials/ (accessed December2013).
8.
PersaudD., GayH., ZiemniakC., et. al.. (2013). Absence of detectable HIV-1 viremia after treatment cessation in an infant. NEJM, 369, 1828–1835.
9.
Science Daily (2013). Child born with HIV still in remission after 18 months off treatment. Available at ww.sciencedaily.com/releases/2013/10/131023183258.htm (accessed December2013).
